Latest Commercialisation News

Page 17 of 239
New Frontier Minerals advanced its copper and rare earths portfolio during FY2026, but the annual report highlights a material uncertainty over its ability to continue as a going concern. The company ended the year with $1.23 million in cash after a $2.25 million placement and ongoing exploration spending.
Maxwell Dee
Maxwell Dee
29 Sept 2026
Green360 Technologies has moved its MKX metakaolin product from testing into commercial supply, securing a binding agreement with Holcim Australia while cutting annualised fixed cash costs by about $1.6 million. The progress comes against a $4.25 million FY2026 loss, $3.93 million in operating cash outflows and an explicit need to prove the business can scale before its cash buffer runs down.
Victor Sage
Victor Sage
29 Sept 2026
TradeWindow is targeting 13% to 18% revenue growth in FY27 and expects to approach EBITDA breakeven, while preparing to shift its primary listing from the NZX to the ASX. The freight software company also reported rising recurring revenue, stronger customer economics and NZ$4.0 million in cash at 30 June 2026.
Victor Sage
Victor Sage
29 Sept 2026
Li-S Energy has narrowed its FY26 loss and reached several commercialisation milestones, including a 2C Power Cell, international shipping approvals and its first lithium foil sale. But the ASX battery developer still needs customer offtake and fresh funding before its proposed 1 GWh manufacturing expansion can become reality.
Victor Sage
Victor Sage
29 Sept 2026
RMA Global has replaced its chief executive and moved to a new chair as it targets a simpler, faster and more profitable business across Australia, New Zealand and the United States. The company has set an EBITDA improvement objective for FY27, but has not yet quantified the plan.
Sophie Babbage
Sophie Babbage
29 Sept 2026
Argent BioPharma has secured exclusive commercialisation rights to selected Tollovir, Tollovid and NutraVir antiviral products in a worldwide deal excluding China. The agreement adds a new commercial pillar alongside CimetrA®, but does not itself grant pharmaceutical development rights or establish clinical efficacy.
Victor Sage
Victor Sage
29 Sept 2026
Structural Monitoring Systems (ASX:SMN) delivered record FY26 revenue, a sharp lift in profit and $6.0 million of free cash flow as its avionics business outpaced contract manufacturing. The balance sheet is now free of bank debt, but the next leg of the story still depends on FAA approvals and converting CVM technology into commercial revenue.
Victor Sage
Victor Sage
29 Sept 2026
Patrys has moved its injectable quetiapine program into human testing, while its FY2026 annual report warns the company will need further funding within 12 months. The company ended the year with $3.36 million in cash after raising capital and acquiring the RLS-2202 development program.
Victor Sage
Victor Sage
28 Sept 2026
Micro-X has secured an eight-month, US$0.75 million contract extension from the US Department of Homeland Security to upgrade its miniature CT baggage scanner for scaled manufacturing. The award advances a technology platform towards possible commercial use, but does not yet represent a product sale or customer deployment.
Sophie Babbage
Sophie Babbage
28 Sept 2026
WhiteHawk has secured an unsecured A$1.5 million facility and says it does not currently expect to raise equity, after cutting annualised operating costs by about A$1.24 million. The funding comes at a 16% interest rate and must be repaid in full at maturity, leaving execution and cash receipts central to the plan.
Victor Sage
Victor Sage
28 Sept 2026
AnteoTech reduced its FY2026 loss and strengthened its balance sheet, but auditors warned that a material uncertainty remains over the company’s ability to continue as a going concern. Commercial revenue fell sharply as battery and diagnostics opportunities remained largely in evaluation or negotiation.
Victor Sage
Victor Sage
28 Sept 2026
First Graphene expanded its product range and international footprint in FY2026, lifting revenue while narrowing its annual loss. But the company says continued operations depend on securing further equity funding, putting commercial execution and liquidity at the centre of its next phase.
Victor Sage
Victor Sage
25 Sept 2026

Browse the archive

Full archive